---
document_datetime: 2025-12-02 04:57:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vyjuvek.html
document_name: vyjuvek.html
version: success
processing_time: 0.108651
conversion_datetime: 2025-12-28 01:55:44.84327
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vyjuvek

[RSS](/en/individual-human-medicine.xml/256038)

##### Authorised

This medicine is authorised for use in the European Union

beremagene geperpavec Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vyjuvek](#news-on)
- [More information on Vyjuvek](#related-medicines)

- Application under evaluation
- CAT draft opinion
- CHMP opinion
- European Commission decision

## Overview

Vyjuvek is a medicine used to treat wounds in patients with dystrophic epidermolysis bullosa. Dystrophic epidermolysis bullosa is an inherited disease of the skin that makes the skin very fragile and causes severe blistering and scarring. Vyjuvek is intended for patients with dystrophic epidermolysis bullosa who have mutations affecting the *COL7A1 (* collagen type VII alpha 1 chain) gene.

Dystrophic epidermolysis bullosa is rare, and Vyjuvek was designated an 'orphan medicine' (a medicine used in rare diseases) on 16 April 2018. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2012) .

Vyjuvek contains the active substance beremagene geperpavec.

Expand section

Collapse section

## How is Vyjuvek used?

Vyjuvek can only be obtained with a prescription and should be started by a healthcare professional experienced in the management of patients with dystrophic epidermolysis bullosa.

Vyjuvek is available as a gel that is applied to wounds once a week. It might not be possible to start treatment of all wounds at the same time due to a maximum weekly recommended dose of the medicine. Vyjuvek should be applied to wounds until they are closed; it should not be used if no wounds are present.

A healthcare professional should apply Vyjuvek. Patients or caregivers may also apply Vyjuvek after training, if the healthcare professional considers it appropriate.

For more information about using Vyjuvek, see the package leaflet or contact your doctor or pharmacist.

## How does Vyjuvek work?

Patients with dystrophic epidermolysis bullosa have a mutation (change) in the *COL7A1* gene. This mutation means their skin cells are not able to make a working form of a protein called type VII collagen (COL7), which helps to keep the layers of the skin together. The active substance in Vyjuvek is beremagene geperpavec, which consists of a virus (herpes simplex 1) that has been modified to contain the *COL7A1* gene. When Vyjuvek is applied to the wounds, the *COL7A1* gene is delivered into the skin cells, enabling them to produce the COL7 protein. This protein helps the layers of the skin to hold together, thereby promoting wound healing.

The virus used in this medicine cannot replicate or cause disease in humans.

## What benefits of Vyjuvek have been shown in studies?

A main study involving 31 patients aged 1 to 44 years with dystrophic epidermolysis bullosa found that Vyjuvek was effective at healing wounds. Each patient received treatment for two wounds: one wound was treated with Vyjuvek and the other with placebo (a dummy treatment). At 6 months, 67% (21 out of 31) of the wounds treated with Vyjuvek were completely healed, compared with 22% (7 out of 31) of those treated with placebo.

## What are the risks associated with Vyjuvek?

For the full list of side effects and restrictions with Vyjuvek, see the package leaflet.

The most common side effects with Vyjuvek (which may affect up to 1 in 10 people) include chills and pruritus (itching).

## Why is Vyjuvek authorised in the EU?

There is an unmet clinical need in the treatment of dystrophic epidermolysis bullosa, and persistent skin lesions caused by the disease represent a great physical, emotional and psychological burden for patients. Vyjuvek was shown to be effective at healing wounds and has a manageable safety profile.

The European Medicines Agency therefore decided that Vyjuvek's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Vyjuvek?

The company that markets Vyjuvek must provide results from a study on the long-term safety of Vyjuvek in patients with dystrophic epidermolysis bullosa with mutations in the *COL7A1* gene, including in patients younger than 6 months of age.

The company will also provide educational materials for healthcare professionals on how to properly store, prepare and apply Vyjuvek. Patients and caregivers will also receive educational materials on the use of Vyjuvek.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vyjuvek have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vyjuvek are continuously monitored. Suspected side effects reported with Vyjuvek are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vyjuvek

Vyjuvek received a marketing authorisation valid throughout the EU on 23 April 2025.

Vyjuvek : EPAR - Medicine overview

Reference Number: EMA/82143/2025

English (EN) (115.58 KB - PDF)

**First published:** 06/05/2025

[View](/en/documents/overview/vyjuvek-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-525)

български (BG) (137.48 KB - PDF)

**First published:**

06/05/2025

[View](/bg/documents/overview/vyjuvek-epar-medicine-overview_bg.pdf)

español (ES) (113.38 KB - PDF)

**First published:**

06/05/2025

[View](/es/documents/overview/vyjuvek-epar-medicine-overview_es.pdf)

čeština (CS) (135.44 KB - PDF)

**First published:**

06/05/2025

[View](/cs/documents/overview/vyjuvek-epar-medicine-overview_cs.pdf)

dansk (DA) (112.12 KB - PDF)

**First published:**

06/05/2025

[View](/da/documents/overview/vyjuvek-epar-medicine-overview_da.pdf)

Deutsch (DE) (116.04 KB - PDF)

**First published:**

06/05/2025

[View](/de/documents/overview/vyjuvek-epar-medicine-overview_de.pdf)

eesti keel (ET) (110.6 KB - PDF)

**First published:**

06/05/2025

[View](/et/documents/overview/vyjuvek-epar-medicine-overview_et.pdf)

ελληνικά (EL) (134.28 KB - PDF)

**First published:**

06/05/2025

[View](/el/documents/overview/vyjuvek-epar-medicine-overview_el.pdf)

français (FR) (114.31 KB - PDF)

**First published:**

06/05/2025

[View](/fr/documents/overview/vyjuvek-epar-medicine-overview_fr.pdf)

hrvatski (HR) (134.14 KB - PDF)

**First published:**

06/05/2025

[View](/hr/documents/overview/vyjuvek-epar-medicine-overview_hr.pdf)

italiano (IT) (112.8 KB - PDF)

**First published:**

06/05/2025

[View](/it/documents/overview/vyjuvek-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (152.74 KB - PDF)

**First published:**

06/05/2025

[View](/lv/documents/overview/vyjuvek-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (135.27 KB - PDF)

**First published:**

06/05/2025

[View](/lt/documents/overview/vyjuvek-epar-medicine-overview_lt.pdf)

magyar (HU) (135.26 KB - PDF)

**First published:**

06/05/2025

[View](/hu/documents/overview/vyjuvek-epar-medicine-overview_hu.pdf)

Malti (MT) (137.45 KB - PDF)

**First published:**

06/05/2025

[View](/mt/documents/overview/vyjuvek-epar-medicine-overview_mt.pdf)

Nederlands (NL) (113.15 KB - PDF)

**First published:**

06/05/2025

[View](/nl/documents/overview/vyjuvek-epar-medicine-overview_nl.pdf)

polski (PL) (136.98 KB - PDF)

**First published:**

06/05/2025

[View](/pl/documents/overview/vyjuvek-epar-medicine-overview_pl.pdf)

português (PT) (114.3 KB - PDF)

**First published:**

06/05/2025

[View](/pt/documents/overview/vyjuvek-epar-medicine-overview_pt.pdf)

română (RO) (133.24 KB - PDF)

**First published:**

06/05/2025

[View](/ro/documents/overview/vyjuvek-epar-medicine-overview_ro.pdf)

slovenčina (SK) (134.39 KB - PDF)

**First published:**

06/05/2025

[View](/sk/documents/overview/vyjuvek-epar-medicine-overview_sk.pdf)

slovenščina (SL) (133.42 KB - PDF)

**First published:**

06/05/2025

[View](/sl/documents/overview/vyjuvek-epar-medicine-overview_sl.pdf)

Suomi (FI) (110.65 KB - PDF)

**First published:**

06/05/2025

[View](/fi/documents/overview/vyjuvek-epar-medicine-overview_fi.pdf)

svenska (SV) (110.7 KB - PDF)

**First published:**

06/05/2025

[View](/sv/documents/overview/vyjuvek-epar-medicine-overview_sv.pdf)

Vyjuvek : EPAR - Risk management plan

English (EN) (534.05 KB - PDF)

**First published:** 06/05/2025

[View](/en/documents/rmp/vyjuvek-epar-risk-management-plan_en.pdf)

## Product information

Vyjuvek : EPAR - Product information

English (EN) (966.18 KB - PDF)

**First published:** 06/05/2025

**Last updated:** 28/07/2025

[View](/en/documents/product-information/vyjuvek-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-25)

български (BG) (870.4 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/bg/documents/product-information/vyjuvek-epar-product-information_bg.pdf)

español (ES) (745.63 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/es/documents/product-information/vyjuvek-epar-product-information_es.pdf)

čeština (CS) (810.52 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/cs/documents/product-information/vyjuvek-epar-product-information_cs.pdf)

dansk (DA) (751.68 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/da/documents/product-information/vyjuvek-epar-product-information_da.pdf)

Deutsch (DE) (833.58 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/de/documents/product-information/vyjuvek-epar-product-information_de.pdf)

eesti keel (ET) (747.08 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/et/documents/product-information/vyjuvek-epar-product-information_et.pdf)

ελληνικά (EL) (858.3 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/el/documents/product-information/vyjuvek-epar-product-information_el.pdf)

français (FR) (782.76 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/fr/documents/product-information/vyjuvek-epar-product-information_fr.pdf)

hrvatski (HR) (838.04 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/hr/documents/product-information/vyjuvek-epar-product-information_hr.pdf)

íslenska (IS) (741.75 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/is/documents/product-information/vyjuvek-epar-product-information_is.pdf)

italiano (IT) (791.79 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/it/documents/product-information/vyjuvek-epar-product-information_it.pdf)

latviešu valoda (LV) (827.98 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/lv/documents/product-information/vyjuvek-epar-product-information_lv.pdf)

lietuvių kalba (LT) (853.98 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/lt/documents/product-information/vyjuvek-epar-product-information_lt.pdf)

magyar (HU) (798.29 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/hu/documents/product-information/vyjuvek-epar-product-information_hu.pdf)

Malti (MT) (878.13 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/mt/documents/product-information/vyjuvek-epar-product-information_mt.pdf)

Nederlands (NL) (763.47 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/nl/documents/product-information/vyjuvek-epar-product-information_nl.pdf)

norsk (NO) (747.8 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/no/documents/product-information/vyjuvek-epar-product-information_no.pdf)

polski (PL) (837.26 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/pl/documents/product-information/vyjuvek-epar-product-information_pl.pdf)

português (PT) (750.03 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/pt/documents/product-information/vyjuvek-epar-product-information_pt.pdf)

română (RO) (827.33 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/ro/documents/product-information/vyjuvek-epar-product-information_ro.pdf)

slovenčina (SK) (830.05 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/sk/documents/product-information/vyjuvek-epar-product-information_sk.pdf)

slovenščina (SL) (821.74 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/sl/documents/product-information/vyjuvek-epar-product-information_sl.pdf)

Suomi (FI) (770.8 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/fi/documents/product-information/vyjuvek-epar-product-information_fi.pdf)

svenska (SV) (780.56 KB - PDF)

**First published:**

06/05/2025

**Last updated:**

28/07/2025

[View](/sv/documents/product-information/vyjuvek-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000281025 26/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vyjuvek : EPAR - All authorised presentations

English (EN) (80.98 KB - PDF)

**First published:** 06/05/2025

[View](/en/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-565)

български (BG) (55.27 KB - PDF)

**First published:**

06/05/2025

[View](/bg/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_bg.pdf)

español (ES) (52.32 KB - PDF)

**First published:**

06/05/2025

[View](/es/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_es.pdf)

čeština (CS) (55.59 KB - PDF)

**First published:**

06/05/2025

[View](/cs/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (54.06 KB - PDF)

**First published:**

06/05/2025

[View](/da/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (55.73 KB - PDF)

**First published:**

06/05/2025

[View](/de/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.09 KB - PDF)

**First published:**

06/05/2025

[View](/et/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (61.43 KB - PDF)

**First published:**

06/05/2025

[View](/el/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_el.pdf)

français (FR) (52.44 KB - PDF)

**First published:**

06/05/2025

[View](/fr/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (65.8 KB - PDF)

**First published:**

06/05/2025

[View](/hr/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (95.34 KB - PDF)

**First published:**

06/05/2025

[View](/is/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_is.pdf)

italiano (IT) (52.54 KB - PDF)

**First published:**

06/05/2025

[View](/it/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.51 KB - PDF)

**First published:**

06/05/2025

[View](/lv/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (61.41 KB - PDF)

**First published:**

06/05/2025

[View](/lt/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (65.6 KB - PDF)

**First published:**

06/05/2025

[View](/hu/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (66.23 KB - PDF)

**First published:**

06/05/2025

[View](/mt/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (52.08 KB - PDF)

**First published:**

06/05/2025

[View](/nl/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (82.52 KB - PDF)

**First published:**

06/05/2025

[View](/no/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_no.pdf)

polski (PL) (64.45 KB - PDF)

**First published:**

06/05/2025

[View](/pl/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_pl.pdf)

português (PT) (53.33 KB - PDF)

**First published:**

06/05/2025

[View](/pt/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_pt.pdf)

română (RO) (55.55 KB - PDF)

**First published:**

06/05/2025

[View](/ro/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (55.45 KB - PDF)

**First published:**

06/05/2025

[View](/sk/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (60.14 KB - PDF)

**First published:**

06/05/2025

[View](/sl/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (51.5 KB - PDF)

**First published:**

06/05/2025

[View](/fi/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (53.05 KB - PDF)

**First published:**

06/05/2025

[View](/sv/documents/all-authorised-presentations/vyjuvek-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vyjuvek Active substance Beremagene geperpavec International non-proprietary name (INN) or common name beremagene geperpavec Therapeutic area (MeSH) Epidermolysis Bullosa Dystrophica Anatomical therapeutic chemical (ATC) code D03AX16

### Pharmacotherapeutic group

Preparations for treatment of wounds and ulcers

### Therapeutic indication

Vyjuvek is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the *collagen type VII alpha 1 chain (COL7A1)* gene, from birth

## Authorisation details

EMA product number EMEA/H/C/006330

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Krystal Biotech Netherlands B.V.

Atrium Gebouw Strawinskylaan 3051 1077 ZX Amsterdam The Netherlands

Opinion adopted 27/02/2025 Marketing authorisation issued 23/04/2025 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vyjuvek : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (191.91 KB - PDF)

**First published:** 30/06/2025

[View](/en/documents/procedural-steps-after/vyjuvek-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Vyjuvek : Orphan Maintenance Assessment Report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000233504

English (EN) (267.64 KB - PDF)

**First published:** 06/05/2025

[View](/en/documents/orphan-maintenance-report/vyjuvek-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Vyjuvek : EPAR - Public assessment report

Adopted

Reference Number: EMA/98574/2025

English (EN) (3.33 MB - PDF)

**First published:** 06/05/2025

**Last updated:** 30/09/2025

[View](/en/documents/assessment-report/vyjuvek-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vyjuvek

Adopted

Reference Number: EMA/CHMP/52904/2025

English (EN) (106.02 KB - PDF)

**First published:** 28/02/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vyjuvek_en.pdf)

#### News on Vyjuvek

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-february-2025) 28/02/2025

[First topical gene therapy treatment for dystrophic epidermolysis bullosa](/en/news/first-topical-gene-therapy-treatment-dystrophic-epidermolysis-bullosa) 28/02/2025

#### More information on Vyjuvek

- [EU/3/18/2012 - orphan designation for treatment of epidermolysis bullosa](/en/medicines/human/orphan-designations/eu-3-18-2012)

**This page was last updated on** 30/06/2025

## Share this page

[Back to top](#main-content)